Results 101 to 110 of about 775,328 (297)

Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer.

Annals of Oncology, 2019
BACKGROUND A high percentage of patients diagnosed with localized colon cancer (CC) will relapse after curative treatment. Although pathological staging currently guides our treatment decisions, there are no biomarkers determining minimal residual ...
N. Tarazona, N. Tarazona, F. Gimeno-Valiente, V. Gambardella, V. Gambardella, S. Zuniga, P. Rentero-Garrido, M. Huerta, Susana Roselló, Susana Roselló, C. Martínez-Ciarpaglini, J. Carbonell-Asins, F. Carrasco, F. Carrasco, A. Ferrer-Martínez, A. Ferrer-Martínez, G. Bruixola, T. Fleitas, T. Fleitas, J. M. Martín, J. M. Martín, R. Tébar-Martínez, D. Moro, J. Castillo, A. Espí, D. Roda, D. Roda, A. Cervantes, A. Cervantes   +28 more
semanticscholar   +1 more source

Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma

Frontiers in Oncology, 2020
In the last years, the life expectancy of multiple myeloma (MM) patients has substantially improved thanks to the availability of many new drugs. Our ability to induce deep responses has improved as well, and the treatment goal in patients tolerating ...
S. Oliva, M. D’Agostino, M. Boccadoro, A. Larocca   +3 more
semanticscholar   +1 more source

The prognostic impact of minimal residual disease in patients with chronic lymphocytic leukemia requiring first-line therapy

Haematologica, 2014
A proportion of patients with chronic lymphocytic leukemia achieve a minimal residual disease negative status after therapy. We retrospectively evaluated the impact of minimal residual disease on the outcome of 255 consecutive patients receiving any ...
Rodrigo Santacruz, Neus Villamor, Marta Aymerich, Alejandra Martínez-Trillos, Cristina López, Alba Navarro, María Rozman, Sílvia Beà, Cristina Royo, Maite Cazorla, Dolors Colomer, Eva Giné, Magda Pinyol, Xose S. Puente, Carlos López-Otín, Elías Campo, Armando López-Guillermo, Julio Delgado   +17 more
doaj   +1 more source

Molecular detection of minimal residual disease for patients with leukemia and lymphoma [PDF]

, 1997
Although a complete clinical remission can often be achieved with chemotherapy for patients with leukaemia and lymphoma, relapses still occur. Residual tumour cells probably have survived therapy and account for subsequent disease relapse.
Chan, DW, Chan, VNY, Kwong, YL, Liang, RHS   +3 more
core  

The Efficiency of Glucocorticoid Therapy in Secondary-progressive Course of Multiple Sclerosis [PDF]

, 2018
We have investigated the efficacy of pulse-therapy with glucocorticoids (GC) at different time stages (in debuts, at the recurrent stage and at the stage of progression) of secondary progressive course (SPC) of multiple sclerosis (MS) in 70 patients (57 ...
Vasylovskyy, V. (Vitaliy)
core   +2 more sources

Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study.

Journal of Clinical Oncology, 2019
PURPOSE The MURANO study demonstrated significant progression-free survival (PFS) benefit for fixed-duration venetoclax-rituximab compared with bendamustine-rituximab in relapsed/refractory chronic lymphocytic leukemia.
A. Kater, J. Seymour, P. Hillmen, B. Eichhorst, A. Langerak, C. Owen, M. Verdugo, J. Wu, E. Punnoose, Yanwen Jiang, Jue Wang, M. Boyer, K. Humphrey, M. Mobasher, T. Kipps   +14 more
semanticscholar   +1 more source

CD20 expression has no prognostic role in Philadelphia-negative B-precursor acute lymphoblastic leukemia: new insights from the molecular study of minimal residual disease

Haematologica, 2012
The prognostic significance of CD20 expression in acute lymphoblastic leukemia has been investigated in children and adults but is still a subject of debate.
Francesco Mannelli, Giacomo Gianfaldoni, Tamara Intermesoli, Chiara Cattaneo, Erika Borlenghi, Sergio Cortelazzo, Irene Cavattoni, Enrico Maria Pogliani, Monica Fumagalli, Emanuele Angelucci, Claudio Romani, Fabio Ciceri, Consuelo Corti, Anna Scattolin, Agostino Cortelezzi, Daniele Mattei, Ernesta Audisio, Orietta Spinelli, Elena Oldani, Alberto Bosi, Alessandro Rambaldi, Renato Bassan   +21 more
doaj   +1 more source

Analogue peptides for the immunotherapy of human acute myeloid leukemia [PDF]

, 2015
Accepted manuscript. The final publication is available at: http://link.springer.com/article/10.1007%2Fs00262-015-1762-9The use of peptide vaccines, enhanced by adjuvants, has shown some efficacy in clinical trials.
A Driessche Van, A Gros, A Scardino, A Serrano, A Sevko, A Snyder, A Tsuboi, AB Bakker, Aleksandrs Malinovskis, Andrew Mead, AT Cheuk, AW Purcell, B Engels, B Falini, B Maecker, B Maecker, B Uttenthal, BA Guinn, BA Guinn, Barbara-ann Guinn, C Chaise, C Maccalli, CL Slingluff Jr, D Cilloni, D Mason, DA Gross, DE Speiser, DH Chang, DJ Schwartzentruber, E Estey, E Romano, F Ghiringhelli, FS Hodi, G Khan, H Kobayashi, H Ohminami, HJ Kolb, HJ Stauss, I Bellantuono, J Bae, J Bae, J Fourcade, J Greiner, J Greiner, J Kronke, J Pinilla-Ibarz, J Pinilla-Ibarz, JH Sampson, JJ Molldrem, JL Chen, JL Chen, JN Kochenderfer, JS Ko, JW Wells, K Inoue, K Inoue, K Rezvani, K Rezvani, KM Zirlik, L Chan, L Fong, L Gao, LV Ly, M Harndahl, M Kapp, M Subklewe, MA Cheever, MG Warnock, MM Gubin, MR Parkhurst, MS Bijker, N Hardwick, Nicola R. Hardwick, O Christensen, O Hamid, P Brossart, P Bruggen van der, P Keskinen, PG Maslak, PG Maslak, R Cibotti, RA Padua, RF Schlenk, RJ May, S Frankild, S Hofmann, S Narayan, S Ochsenreither, S Pascolo, S Suekane, S Walter, SH Burg van der, SK Singh, SL Topalian, SP Adams, Susanne Hofmann, T Lovgren, U Keilholz, U Sahin, V Bhardwaj, WS Meng, Y Oka, Z Trajanoski   +102 more
core   +2 more sources

237TiP GUIDE.MRD: A Consortium guiding multi-modal therapies against minimal residual disease (MRD) by liquid biopsy to assess implementation of circulating tumor DNA (ctDNA) in clinical practice to improve patient outcomes [PDF]

, 2023
Klaus Pantel, Claus L. Andersen, Ed Schuuring, Núria Malats, Ellen Heitzer, L. Vat, Estevan P. Kiernan, Emily Chin, J. Carl Barrett, Joshua Kapp, M. Thomas, Marco Gerling, Martin Reck, Matthias Löhr, Paul Hofman, J.T.J.N. Hiltermann, Catherine Alix‐Panabières, Darren J. Smit, Mohan Bolisetty, Maria Karasarides   +19 more
openalex   +1 more source

Development of real-time quantitative polymerase chain reaction assays to track treatment response in retinoid resistant acute promyelocytic leukemia

Frontiers in Oncology, 2011
Molecular detection of minimal residual disease (MRD) has become established to assess remission status and guide therapy in patients with PML-RARA+ acute promyelocytic leukemia (APL).
Jelena V Jovanovic, Kristian eRennie, Dominic eCulligan, Andrew ePeniket, Anne eLennard, Justin eHarrison, Paresh eVyas, Paresh eVyas, David eGrimwade   +8 more
doaj   +1 more source